[go: up one dir, main page]

WO2010060928A3 - Compositions pour le traitement de lésion tissulaire ischémique - Google Patents

Compositions pour le traitement de lésion tissulaire ischémique Download PDF

Info

Publication number
WO2010060928A3
WO2010060928A3 PCT/EP2009/065835 EP2009065835W WO2010060928A3 WO 2010060928 A3 WO2010060928 A3 WO 2010060928A3 EP 2009065835 W EP2009065835 W EP 2009065835W WO 2010060928 A3 WO2010060928 A3 WO 2010060928A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
tissue damage
compositions
ischemic tissue
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2009/065835
Other languages
English (en)
Other versions
WO2010060928A2 (fr
Inventor
Patricia Salama Cohen
Juan Carlos RODRÍGUEZ CIMADEVILLA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PROJECH SCIENCE TO TECHNOLOGY SL
Original Assignee
PROJECH SCIENCE TO TECHNOLOGY SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PROJECH SCIENCE TO TECHNOLOGY SL filed Critical PROJECH SCIENCE TO TECHNOLOGY SL
Publication of WO2010060928A2 publication Critical patent/WO2010060928A2/fr
Publication of WO2010060928A3 publication Critical patent/WO2010060928A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un milieu conditionné de neurosphères ou un extrait de celui-ci pour utilisation en tant que médicament pour le traitement de lésion tissulaire ischémique. En particulier, la présente invention concerne l’utilisation desdits milieux conditionnés ou des extraits de ceux-ci pour le traitement d’une lésion ischémique cérébrale, plus particulièrement pour le traitement d’un accident vasculaire cérébral.
PCT/EP2009/065835 2008-11-26 2009-11-25 Compositions pour le traitement de lésion tissulaire ischémique Ceased WO2010060928A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08382067 2008-11-26
EP08382067.0 2008-11-26

Publications (2)

Publication Number Publication Date
WO2010060928A2 WO2010060928A2 (fr) 2010-06-03
WO2010060928A3 true WO2010060928A3 (fr) 2010-10-14

Family

ID=41698365

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/065835 Ceased WO2010060928A2 (fr) 2008-11-26 2009-11-25 Compositions pour le traitement de lésion tissulaire ischémique

Country Status (1)

Country Link
WO (1) WO2010060928A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114645016A (zh) * 2022-05-06 2022-06-21 浙江以和细胞生物科技有限公司 用于早产儿脑出血后遗症的自体生发基质干细胞培养方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030022261A1 (en) * 1998-12-11 2003-01-30 Gage Fred Harrison Co-factors for trophic factors, and methods of use, thereof
WO2008024996A2 (fr) * 2006-08-24 2008-02-28 Johnstone Brian H Production de facteurs neuraux protecteurs et régénérateurs issus de cellules souches et traitement de pathologies du système nerveux

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030022261A1 (en) * 1998-12-11 2003-01-30 Gage Fred Harrison Co-factors for trophic factors, and methods of use, thereof
WO2008024996A2 (fr) * 2006-08-24 2008-02-28 Johnstone Brian H Production de facteurs neuraux protecteurs et régénérateurs issus de cellules souches et traitement de pathologies du système nerveux

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FURUTA M ET AL: "Identification of pleiotrophin in conditioned medium secreted from neural stem cells by SELDI-TOF and SELDI-tandem mass spectrometry", DEVELOPMENTAL BRAIN RESEARCH, ELSEVIER SCIENCE BV, AMSTERDAM, NL LNKD- DOI:10.1016/J.DEVBRAINRES.2004.06.014, vol. 152, no. 2, 17 September 2004 (2004-09-17), pages 189 - 197, XP004559716, ISSN: 0165-3806 *
LIM H C ET AL: "Neuroprotective effect of neural stem cell-conditioned media in in vitro model of Huntington's disease", NEUROSCIENCE LETTERS, LIMERICK, IE LNKD- DOI:10.1016/J.NEULET.2008.02.035, vol. 435, no. 3, 25 April 2008 (2008-04-25), pages 175 - 180, XP022655790, ISSN: 0304-3940, [retrieved on 20080310] *
TAUPIN PHILIPPE ET AL: "FGF-2-responsive neural stem cell proliferation requires CCg, a novel autocrine/paracrine cofactor", November 2000, NEURON, VOL. 28, NR. 2, PAGE(S) 385-397, ISSN: 0896-6273, XP002593520 *

Also Published As

Publication number Publication date
WO2010060928A2 (fr) 2010-06-03

Similar Documents

Publication Publication Date Title
WO2009089494A3 (fr) Compositions pharmaceutiques
EP2192911B8 (fr) Extrait de plantes de cannabis à faible thc pour le traitement de maladies
WO2010069532A8 (fr) Anticorps dirigés contre l'angiopoïétine 2 humaine
WO2009012871A3 (fr) Capsule filtrant les uv
MX2012004551A (es) Nuevas composiciones para prevenir y/o tratar trastornos de almacenamiento lisosomal.
WO2011077043A3 (fr) Derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
WO2010000877A3 (fr) Formulation à base de bisabolol et de [6]-paradol produisant un effet apaisant sur les irritations
SG10201803862UA (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
WO2008070268A3 (fr) Compositions pharmaceutiques
SI2356109T1 (sl) Sestavki in postopki za zdravljenje motenj zaradi uživanja alkohola, bolečine in drugih bolezni
WO2013034855A3 (fr) Association de carraghénane et de c-glycoside et leurs utilisations
IL201921A0 (en) 1,3-dihydroimidazol-2-thione derivative as inhibitors of dopamine-beta-hydroxylase
EP2167083A4 (fr) Nouveaux 1- hétéroaryl-3-azabicycloý3.1.0¨hexanes, leurs méthodes de préparation et leur utilisation comme médicaments
WO2012120098A3 (fr) Pigments traités hydrophiles dispersibles dans une composition cosmétique
WO2010018526A3 (fr) Composition pour le traitement de la peau
WO2010046061A3 (fr) Préparations cosmétiques et/ou pharmaceutiques
WO2011122872A3 (fr) Composition comprenant du coumestrol ou un extrait de fèves contenant du coumestrol
WO2011048554A3 (fr) Association d'un lysat de probiotique et d'un derive c-glycoside
WO2012017435A3 (fr) Extraits de soja destinés au traitement de troubles hépatiques
WO2010124085A3 (fr) Compositions et méthodes pour prévenir et traiter une maladie utérine
PT2280596T (pt) Disco para uso agrícola, particularmente usado para lavrar campo
WO2009120368A3 (fr) Traitement de lésions cérébrales utilisant des cellules sanguines de cordon ombilical
WO2009090085A8 (fr) Traitement d'une pression intra-oculaire anormale
MX2011006721A (es) Formulacion farmaceutica de fenofibrato nanonizado.
WO2011026577A3 (fr) Préparations dotées d'amines polymères non hydrosolubles pour réduire des odeurs corporelles

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09760853

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09760853

Country of ref document: EP

Kind code of ref document: A2